Cell proliferation markers in human solid tumors: Assessing their impact in clinical oncology

Methods in Cell Biology

Volumn 64, Issue 64, 2001, Pages 359-384

  Daidone, Maria Grazia ^a   Costa, Aurora ^a   Silvestrini, Rosella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CELL CYCLE S PHASE; CELL DIVISION; CHEMISTRY; HUMAN; MITOSIS; NEOPLASM; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS;

ANTIGENS, NEOPLASM; CELL DIVISION; DNA, NEOPLASM; HUMANS; MITOSIS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; S PHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0035228421     PISSN: 0091679X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0091-679x(01)64022-6     Document Type: Article

References (118)

1. Aas, T., Børrresen, A. L., Geisler, S., Smith Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lonning, P. E. (1996). Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2, 811-814.
2. Ahnen, D. J., Feigl, P., Quan, G., Fenoglio-Preiser, C., Lovato, L. C., Bunn, P. A., Jr., Stemmerman, G., Wells, J. D., Macdonald, J. S., and Meyskens, F. L., Jr. (1998). Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group Study. Cancer Res. 58, 1149-1158.
3. Alama, A., Costantini, M., Repetto, L., Cone, P. F., Serrano, J., Nicolin, A., Barbieri, F., Ardizzoni, A., and Bruzzi, P. (1990). Thymidine labelling index as prognostic factor in resected non-small cell lung cancer. Eur. J. Cancer 26, 622-625.
4. Altman, D. G., and Lyman, G. H. (1998). Methodological challenges in the evaluation of prognostic factors in breast cancer. Br. Cancer Res. Treat. 52, 289-303.
5. Amadori, D., and Silvestrini, R. (1998). Prognostic and predictive value of thymidine labelling index in breast cancer. Breast Cancer Res. Treat. 51, 267-281.
6. Amadori, D., Bonaguri, C., Nanni, O., Gentilini, P., Lundi, N., Zoli, W., Riccobon, A., Vio, A., and Saragoni, A. (1991). Cell kinetics and hormonal features in relation to pathological stage in breast cancer. Breast Cancer Res. Treat. 18, 19-25.
7. Amadori, D., Volpi, A., Callea, A., Amaducci, L., Morgagni, S., Magni, E., and Nanni, O. (1994). Clinical relevance of cell kinetics in breast cancer. Ann. N.Y. Acad. Sci. 698, 186-192.
8. Amadori, D., Volpi, A., Maltoni, R., Nanni, O., Amaducci, L., Amadori, A., Giunchi, D. C., Vio, A., Saragoni, A., and Silvestrini, R. (1997). Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study. Breast Cancer Res. Treat. 43, 7-14.
9. Amadori, D., Nanni, O., Marangolo, M., Pacini, P., Ravaioli, A., Rossi, A., Gambi, A., Catalano, G., Perroni, D., Scarpi, E., Casadei-Giunchi, D., Tienghi, A., Becciolini, A., and Volpi, A. (2000). DFS advantage of adjuvant CMF in node-negative rapidly proliferating breast cancer patients: A randomised multicentre study. J. Clin. Oncol. in press.
10. Auvinen, A., Isola, J., Visakorpi, T., Koivula, T., Virtanen, S., and Hakama, M. (1994). Overexpression of p53 and long-term survival in colon carcinoma. Br. J. Cancer 70, 293-296.
11. Baldini, E., Giannessi, P. G., Collecchi, P., Naccarato, A. G., Passoni, A., Bevilacqua, G., and Conte, P. F. (1996). Effects of primary chemotherapy on proliferative activity, IGF-1R and bcl2 expression in locally advanced breast cancer (Meeting abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 15, A139.
12. Barnes, D. M., and Gillett, C. E. (1995). Determination of cell proliferation. J. Clin. Pathol. Mol. Pathol. 48, M2-M5.
13. Bauer, K. D., Lincoln, S. T., Vera-Roman, J. M., Wallemark, C. B., Chmiel, J. S., Madurski, M. L., Murad, T., and Scarpelli, D. G. (1987). Prognostic implications of proliferative activity and DNA aneuploidy in colonie adenocarcinomas. Lab. Invest. 57, 329-335.
14. Bonadonna, G., Valagussa, P., Tancini, G., Rossi, A., Brambilla, C., Zambetti, M., Bignami, P., Di Fronzo, G., and Silvestrini, R. (1986). Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancers. NCI Monogr. 1, 45-49.
15. Bosman, F. T. (1995). Prognostic value of pathological characteristics of colorectal cancer. Eur. J. Cancer 31A, 1216-1221.
16. Briffod, M., Tubiana-Hulin, M., Spyratos, F., Hacène, K., Pallud, C., Mayras, C., and Rouessé, J. (1995). Fine-needle cytopunctures for early prediction of tumor response to preoperative chemotherapy in 94 operable breast carcinomas (Meeting abstract). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14, A261.
17. Brown, R. W., Allred, D. C., Clark, G. M., Osborne, C. K., and Hilsenbeck, S. G. (1996). Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin. Cancer Res. 2, 585-592.
18. Cascinu, S., Ligi, M., Graziano, F., Del Ferro, E., Valentini, M., Grianti, C., Bartolucci, M., and Catalano, G. (1998). S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma. Implications for adjuvant chemotherapy. Cancer 83, 1081-1085.
19. Cattoretti, G., Becker, M. H. G., Key, G., Duchrow, M., Schluter, C., Galle, J., and Gerdes, J. (1992). Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol. 168, 357-363.
20. Chevillard, S., Pouillart, P., Beldjord, C., Asselain, B., Beuzeboc, P., Magdelenat, H., and Viel, P. (1996). Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77, 292-300.
21. Clark, G. M., Dressler, L. G., Owens, M. A., Pound, G., Oldaker, T., and McGuire, W. L. (1989). Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N. Engl. J. Med. 320, 627-633.
22. Clark, G. M., Mathieu, M. C., Owens, M. A., Dressler, L. G., Eudey, L., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., and Abeloff, M. D. (1992). Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J. Clin. Oncol. 10, 428-432.
23. Clurman, B. E., and Roberts, J. M. (1995). Cell cycle and cancer. J. Natl. Cancer Inst. 87, 1499.
24. Collecchi, P., Baldini, E., Giannessi, P., Naccarato, A. G., Passoni, A., Gardin, G., Roncella, M., Evangelista, G., Bevilacqua, G., Conte, P. F., et al. (1998). Primary chemotherapy in locally advanced breast cancer (LABC): Effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. Eur. J. Cancer 34, 1701-1704.
25. Cooke, T. G., Stanton, P. D., Winstanley, J., Murray, G. D., Croton, R., Holt, S., and George, W. D. (1992). Long term prognostic significance of thymidine labeling index in primary breast cancer. Eur. J. Cancer 28, 424-426.
26. Cosimelli, M., D'Agnano, I., Tedesco, M., D'Angelo, C., Botti, C., Giannarelli, D., Vasselli, S., Cavaliere, F., Zupi, G., and Cavaliere, R. (1998). The role of multiploidy as unfavourable prognostic variable in colorectal cancer. Anticancer Res. 18, 1957-1966.
27. Costa, A., Faranda, A., Scalmati, A., Quagliuolo, V., Colella, G., Ponz, de Leon, M., and Silvestrini, R. (1992). Autoradiographic and flow-cytometric assessment of cell proliferation in primary colorectal cancer: Relationship to DNA ploidy and clinico-pathological features. Int. J. Cancer 50, 719-723.
28. Costa, A., Silvestrini, R., Mochen, C., Lequaglie, C., Boracchi, P., Faranda, A., Vessecchia, G., and Ravasi, G. (1996). P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small cell lung cancer. Br. J. Cancer 73, 914-919.
29. Daidone, M. G., Silvestrini, R., Canova, S., Valagussa, P., and Bonadonna, G. (1989). Tumor cell kinetics and course of node-positive (N+) breast cancer. Proc. Am. Soc. Clin. Oncol. 8, 24.
30. Daidone, M. G., Silvestrini, R., Valentinis, B., Ferrari, L., and Bartoli, C. (1990). Changes in cell kinetics induced by primary chemotherapy in breast cancer. Int. J. Cancer 47, 380-383.
31. Daidone, M. G., Silvestrini, R., Luisi, A., Mastore, M., Benini, E., Veneroni, S., Brambilla, C., Ferrari, L., Greco, M., Andreola, S., and Veronesi, U. (1995). Changes in biological markers after primary chemotherapy for breast cancers. Int. J. Cancer 61, 301-305.
32. Daidone, M. G., Veneroni, S., Benini, E., Tomasic, G., Coradini, D., Brambilla, C., Ferrari, L., and Silvestrini, R. (1999). Biological markers and changes induced in their profiles following primary chemotherapy: Relevance on short- and long-term clinical outcome. In "Primary Medical Therapy for Breast Cancer" (A. Howell and M. Dowsett, eds.), pp. 53-72. ESO Scientific Updates, Milan.
33. Daidone, M. G., Luisi, A., Martelli, G., Veneroni, S., Tomasic, G., De Palo, G., and Silvestrini, R. (2000). Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women. Br. J. Cancer 82, 270-277.
34. Dalquen, P., Moch, H., Feichter, G., Lehmann, M., Soler, M., Stulz, P., Jordan, P., Torhorst, J., Mihatsch, M. J., and Sauter, G. (1998). DNA aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small cell lung carcinoma. Virchows Arch. 431, 173-179.
35. Dean, P. N., Gray, J. W., and Dolbeare, F. A. (1982). The analysis and interpretation of DNA distributions measured by flow cytometry. Cytometry 3, 188-195.
36. Dressler, L. G., Seamer, L. C., Owens, M. A., Clark, G. M., and McGuire, W. L. (1988). DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61, 420-427.
37. Filderman, A. E., Silvestri, G. A., Gatsonis, C., Luthringer, D. J., Honig, J., and Flynn, S. D. (1992). Prognostic significance of tumour proliferative fraction and DNA content in stage I non-small cell lung cancer. Am. Rev. Resp. Dis. 146, 707-710.
38. Fisher, B., Gunduz, N., Costantino, J., Fisher, E. R., Edmond, C., Mamounas, E. P., and Siderits, R. (1991). DNA flow cytometric analysis of primary operable breast cancer. Cancer 68, 1465-1469.
39. Frierson, H. F. (1991). The need for improvement in flow cytometric analysis of ploidy and S-phase fraction. Am. J. Clin. Pathol. 96, 439-441.
40. Galand, P., and Degraef, C. (1989). Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labeling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet. 22, 383-392.
41. Gardin, G., Alama, A., Rosso, R., Campora, E., Rapetto, L., Pronzato, P., Merlini, P., Naso, C., Camoriano, A., and Meazza, R. (1994). Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Res. Treat. 32, 311-318.
42. Gentili, C., Sanfilippo, O., and Silvestrini, R. (1981). Cell proliferation in relation to clinical features and relapse in breast cancers. Cancer 48, 974-979.
43. Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., and Stein, H. (1984). Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133, 1710-1715.
44. Gillett, C. E., and Barnes, D. M. (1998). Cell cycle. J. Clin. Pathol. Mol. Pathol. 51, 310-316.
45. Gilliland, R., Williamson, K. E., Wilson, R. H., Anderson, N. H., and Hamilton, P. W. (1996). Colorectal cell kinetics. Br. J. Surg. 83, 739-749.
46. Gion, M., Boracchi, P., Biganzoli, E., and Daidone, M. G. (1999). A guide for reviewing submitted manuscripts (and indications for the design of translational research studies on biomarkers). Int. J. Biol. Markers 13, 123-133.
47. Gratzner, H. G. (1982). Monoclonal antibody to 5-bromo-and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 218, 474-476.
48. Harlow, S. P., Eriksen, B. L., Poggensee, L., Chmiel, J. S., Scarpelli, D. G., Murad, T., and Bauer, K. D. (1991). Prognostic implications of proliferative activity and DNA aneuploidy in Astler-Coller Dukes stage C colonie adenocarcinomas. Cancer Res. 51, 2403-2409.
49. Hayes, D. F., Trock, B., and Harris, A. L. (1998). Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? Br. Cancer Res. Treat. 52, 305-319.
50. Hedley, D. W. (1989). Flow cytometry using paraffin-embedded tissue: Five years on. Cytometry 10, 229-241.
51. Henderson, I. C., and Patek, A. J. (1998). The relationship between prognostic and predictive factors in the management of breast cancer. Br. Cancer Res. Treat. 52, 261-288.
52. Héry, M., Gioanni, J., Lalanne, C. M., Namer, M., and Courdi, A. (1987). The DNA labeling index: A prognostic factor in node-negative breast cancer. Breast Cancer Res. Treat. 9, 207-212.
53. Hietanen, P., Blomqvist, C., Wasenius, V. M., Niskanen, E., Franssila, K., and Nordling, S. (1995). Do DNA ploidy and S-phase fraction in primary tumor predict the response to chemotherapy in metastatic breast cancer? Br. J. Cancer 71, 1029-1032.
54. Hilsenbeck, S. G., Ravdin, P. M., de Moor, C. A., Chamnen, G. C., Osborne, C. K., and Clark, G. M. (1998). Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Br. Cancer Res. Treat. 52, 227-237.
55. Honkoop, A. H., van Diest, P. J., de Jong, J. S., Linn, S. C., Giaccone, G., Hoekman, K., Wagstaff, J., and Pinedo, H. M. (1998). Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br. J. Cancer 77, 621-626.
56. Howell, W. M. (1982). Selective staining of nucleolar organizer regions (NORs). In "The Cell Nucleus" (H. Bush and L. Tothblum, eds.), pp. 89-142. Academic Press, New York.
57. Johnston, P. G., and Allegra, C. J. (1995). Colorectal cancer biology: Clinical implications. Semin. Oncol. 22, 418-432.
58. Kallioniemi, O., Blanco, G., Alavaikko, M., Hietanen, T., Mattila, J., Lauslahti, K., Lehtinen, M., and Koivula, T. (1988). Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. Cancer 62, 2183-2190.
59. Kute, T. E., Quadri, Y., Muss, H., Zbieranski, N., Cirrincione, C., Berry, D. A., Barcos, M., Thor, A. P., Liu, E., Koerner, F., et al. (1995). Flow cytometry in node-positive breast cancer: Cancer and Leukemia Group B protocol 8869. Cytometry 22, 297-306.
60. Le Chevalier, T., Arriagada, R., Quoix, E., Ruffie, P., Martin, M., Tarayre, M., Douillard, J. Y., and Laplanche, A. (1991). Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients. J. Natl. Cancer Inst. 83, 417-423.
61. MacGrogan, G., Mauriac, L., Durand, M., Bonichon, F., Trojani, M., de Mascarel, I., and Coindre, J. M. (1996). Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, Mib1, pS2 and GST. Br. J. Cancer 74, 1458-1465.
62. McGuire, W. L. (1991). Breast cancer prognostic factors: Evaluation guidelines. J. Natl. Cancer Inst. 83, 154-155.
63. Marino, P., Pampallona, S., Preatoni, A., Cantoni, A., and Invernizzi, F. (1994). Chemotherapy versus supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature. Chest 106, 861-865.
64. Matturri, L., Lavezzi, A. M., Grignani, F., Salomoni, G., and Roviaro, G. C. (1994). The prognostic value of cell proliferation in non-small cell lung cancer assessed with tritiated thymidine and anti-PCNA antibodies. Eur. J. Cancer 30A, 1397-1398.
65. Meyer, J. S., and Coplin, M. D. (1988). Thymidine labeling index, flow cytometric S-phase. Measurement, and DNA index in human tumors. Am. J. Clin. Pathol. 89, 586-589.
66. Meyer, J. S., and Lee, J. Y. (1980). Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res. 40, 1890-1896.
67. Meyer, J. S., and Province, M. (1988). Proliferative index of breast carcinoma by thymidine labeling: Prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res. Treat. 12, 191-199.
68. Meyer, J. S., Friedman, E., and McCrote, M. M. (1983). Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51, 1879-1886.
69. Meyer, J. S., Prey, M. U., and Babcock, D. S. (1986). Breast carcinoma cell kinetics, morphology, stage and host characteristics. Lab. Invest. 54, 41-51.
70. Mushika, M., Miwa, T., Suzuoki, Y., Hayashi, K., Masaki, S., and Kaneda, T. (1988). Detection of proliferative cells in dysplasia, carcinoma in situ, and invasive carcinoma of the uterine cervix by monoclonal antibody against DNA polymerase α. Cancer 61, 1182-1186.
71. Muss, H. B., Kute, T. E., Case, L. D., Smith, L. R., Booher, C., Long, R., Kammire, L., Gregory, B., and Brockschmidt, J. K. (1989). The relation of flow cytomety to clinical and biological characteristics in women with node negative primary breast cancer. Cancer 64, 1894-1900.
72. Nelson, J. S., and Schiffer, L. M. (1973). Autoradiographic detection of DNA polymerase containing nuclei in sarcoma 180 ascites cells. Cell Tissue Kinet. 6, 45-54.
73. O'Reilly, S. M., Camplejohn, R. S., Barnes, D. M., Millis, R. R., Rubens, R. D., and Richards, M. A. (1990a). Node-negative breast cancer: Prognostic subgroups defined by tumor size and flow cytometry. J. Clin. Oncol. 8, 2040-2045.
74. O'Reilly, S. M., Camplejohn, R. S., Millis, R. R., Rubens, R. D., and Richards, M. A. (1990b). Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur. J. Cancer 26, 1035-1038.
75. Paradiso, A., Tommasi, S., Mangia, A., Lorusso, V., Simone, G., and De Lena, M. (1990). Tumor proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. Cancer Res. 50, 2958-2962.
76. Paradiso, A., Mangia, A., and Picciariello, M. S. (1991). Fattori prognostici nel carcinoma della mammella operabile N-: Attività proliferativa e caratteristiche clinico patologiche. Folia Oncol. 14, 247-252.
77. Paradiso, A., Mangia, A., Barletta, A., Catino, A. M., Giannuzzi, A., Schittulli, F., Radogna, N., Longo, S., Palmieri, D., and Marzullo, F. (1993). Randomized clinical trial of adjuvant chemotherapy in patients with node negative, fast proliferating breast cancer drug. Drugs 45, 68-74.
78. Pierga, J. Y., Lainé-Bidron, C., Beuzeboc, P., De Cremoux, P., Pouillart, P., and Magdelenat, H. (1997). Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer. Br. J. Cancer 76, 537-540.
79. Pietra, N., Sarli, L., Sansebastiano, G., Jotti, G. S., and Peracchia, A. (1996). Prognostic value of ploidy, cell proliferation kinetics, and conventional clinicopathologic criteria in patients with colorectal carcinoma. Dis. Colon Rectum 39, 494-503.
80. Quinn, C. M., and Wright, N. A. (1990). The clinical assessment of proliferation and growth in human tumours: Evaluation of methods and applications as prognostic variables. J. Pathol. 160, 93-102.
81. Quirke, P., Dixon, M. F., Clayden, A. D., Durdey, P., Dyson, J. E., Williams, N. S., and Bird, C. C. (1987). Prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas. J. Pathol. 151, 285-291.
82. Remvikos, Y., Beuzeboc, P., Zajdela, A., Voillemot, N., Magdelenat, H., and Pouillart, P. (1989). Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J. Natl. Cancer Inst. 81, 1383-1387.
83. Remvikos, Y., Mosseri, V., Asselain, B., Fourquet, A., Voillemot, N., Magdelenat, H., and Pouillart, P. (1997). S-phase fractions of breast cancer predict overall and post-relapse survival. Eur. J. Cancer 33, 581-586.
84. Rozan, S., Vincent-Salomon, A., Zafrani, B., Validire, P., De Cremoux, P., Bernoux, A., Nieruchalski, M., Fourquet, A., Clough, K., Dieras, V., and Pouillart, P. (1998). No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer (Pred. Oncol.) 79, 27-33.
85. Rudas, M., Gnant, M. F., Mittlbock, M., Neumayer, R., Kummer, A., Jakesz, R., Reiner, G., and Reiner, A. (1994). Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation with prognosis. Breast Cancer Res. Treat. 32, 165-175.
86. Schipper, D. L., Wagenmans, M. J. M., Peters, W. H. M., and Wagener, D. J. (1998). Significance of cell proliferation measurement in gastric cancer. Eur. J. Cancer 34, 781-790.
87. Schutte, B., Reynders, M. M. J., Wiggers, T., Arends, J. W., Volovics, L., Bosman, F. T., and Blijham, A. M. (1987). Retrospective analysis of the prognostic significance of DNA content and proliferative activity in large bowel carcinoma. Cancer Res. 47, 5494-5496.
88. Scott, N. A., Rainwater, L. M., Wieand, H. S., Weiland, L. H., Pemberton, J. H., Beart, R. W., Jr., and Lieber, M. M. (1987). The relative prognostic value of flow cytometric DNA analysis and conventional clinicopathologic criteria in patients with operable rectal carcinoma. Dis. Colon Rectum 30, 513-520.
89. Sigurdsson, H., Baldetorp, B., Borg, A., Dalberg, M., Ferno, M., Killander, D., Olsson, H., and Ranstam, J. (1990). Indicators of prognosis in node-negative breast cancer. N. Engl. J. Med. 322, 1045-1049.
90. Silvestrini, R. (1994a). Cell kinetics: Prognostic and therapeutic implications in human tumor. Cell Prolif. 27, 579-596.
91. Silvestrini, R. (on behalf of the SICCAB Group for Quality Control of Cell Kinetic Determinations) (1994b). Quality control for the evaluation of the S-phase fraction by flow cytometry: a multicentric study. Cytometry (Comm. Clin. Cytometry) 18, 11-16.
92. Silvestrini, R., and the SICCAB Group for Quality Control of Cell Kinetic Determination (1991). Feasibility and reproducibility of the 3H-dT labeling index in breast cancer. Cell Prolif. 24, 437-445.
93. Silvestrini, R., Daidone, M. G., Di Fronzo, G., Morabito, A., Valagussa, P., and Bonadonna, G. (1986). Prognostic implication of labelling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Res. Treat. 7, 161-169.
94. Silvestrini, R., Daidone, M. G., Valagussa, P., Salvadori, B., Rovini, D., and Bonadonna, G. (1987). Cell kinetics and prognosis in locally advanced breast cancer. Cancer Treat. Rep. 71, 375-379.
95. Silvestrini, R., Daidone, M. G., Valagussa, P., Di Fronzo, G., Mezzanotte, G., and Bonadonna, G. (1989). Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur. J. Cancer Clin. Oncol. 25, 1165-1171.
96. Silvestrini, R., Muscolino, G., Costa, A., Lequaglie, C., Veneroni, S., Mezzanotte, G., and Ravasi, G. (1991). Could cell kinetics be a predictor of prognosis in non-small cell lung cancer? Lung Cancer 7, 165-170.
97. Silvestrini, R., Daidone, M. G., Del Bino, G., Mastore, M., Di Fronzo, G., and Boracchi, P. (1993a). Prognostic significance of proliferative activity and ploidy in node-negative breast cancer. Ann. Oncol. 4, 213-219.
98. Silvestrini, R., Daidone, M. G., Mastore, M., Di Fronzo, G., Coradini, D., Boracchi, P., Squicciarini, P., Salvadori, B., and Veronesi, U. (1993b). Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J. Clin. Oncol. 11, 1150-1155.
99. Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., Rilke, F., and Veronesi, U. (1994). The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. 86, 499-504.
100. Silvestrini R., Daidone, M. G., and Costa, A. (1995a). Determination of the proliferative fraction in human tumors. In "Cell Growth and Apoptosis. A Pratical Approach" (G. P. Studzinski, ed.), pp. 59-77. IRL Oxford Univ. Press, Oxford.
101. Silvestrini, R., Daidone, M. G., Luisi, A., Boracchi, P., Mezzetti, M., Di Fronzo, G., Andreola, S., and Veronesi, U. (1995b). Biologic and clinico-pathologic factors as indicators of specific relapse types in node-negative breast cancer. J. Clin. Oncol. 13, 697-704.
102. Silvestrini, R., Benini, E., Veneroni, S., Daidone, M. G., Tomasic, G., Squicciarini, P., and Salvadori, B., (1996). P53 and Bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J. Clin. Oncol. 14, 1604-1610.
103. Silvestrini, R., Daidone, M. G., Luisi, A., Boracchi, P., Mezzetti, M., Di Fronzo, G., Andreola, S., Salvadori, B., and Veronesi, U. (1997). Cell proliferation in 3800 node-negative breast cancers: Consistency over time of biological and clinical information provided by 3H-thymidine labelling index. Int J. Cancer (Pred. Oncol.) 74, 122-127.
104. Simonsson, B., Killander, C. F. R., Brenning, G., Kallander C. F., Ahre, A., and Gronowitz, J. S. (1985). Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma. Br. J. Hematol. 61, 215-218.
105. Stål, O., and Nordenskjold, B. (1994). S-phase fraction and survival benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Br. J. Cancer 70, 1258-1263.
106. Stanton, P. D., Cooke, T. G., Oakes, S. J., Winstanley, J., Holt, S., George, W. D., and Murray, G. D. (1992). Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer. Br. J. Cancer 66, 925-929.
107. Sulkes, A., Livingstone, R. B., and Murphy, W. K. (1979). Tritiated thymidine labeling index and response in human breast cancer. J. Natl. Cancer Inst. 62, 513-515.
108. Ten Velde, G. P. M., Schutte, B., Vermeulen, A., Volovics, A., Reynders, M. M., and Blijham, G. H. (1988). Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer. Eur. J. Cancer Clin. Oncol. 24, 455-460.
109. Tubiana, M., and Courdi, A. (1989). Cell proliferation kinetics in human solid tumors: Relation to probability of metastatic dissemination and long-term survival. Radiother. Oncol. 15, 1-18.
110. Tubiana, M., Pejovic, M. H., Chavaudra, G., Contesso, G., and Malaise, E. P. (1984). The long term prognostic significance of the thymidine labeling index in breast cancer. Int J. Cancer 33, 441-445.
111. Tubiana, M., Pejovic, M. H., Koscielny, S., Chavaudra, N., and Malaise, E. (1987). Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int. J. Cancer 44, 17-22.
112. Tumor Marker Expert Panel Members (1996). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J. Clin. Oncol. 14, 2843-2877.
113. Van Diest, P. J., Brugal, G., and Baak, J. P. A. (1998). Proliferation markers in tumours: Interpretation and clinical value. J. Clin. Pathol. 51, 716-724.
114. Volm, M., Drings, P., Mattern, J., Sonka, J., Vogt-Moykopf, I., and Wayss, K. (1985a). Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma. Cancer 56, 1396-1403.
115. Volm, M., Matter, J., Sonka, J., Vogt-Schaden, M., and Wayss, K. (1985b). DNA distribution in non-small-cell lung carcinomas and its relationship to clinical behaviour. Cytometry 6, 348-356.
116. Wenger, C. R., and Clark, G. M. (1998). S-phase fraction and breast cancer - a decade of experience. Br. Cancer Res. Treat. 51, 255-265.
117. Witzig, T. E., Loprinzi, C. L., Gonchoroff, N. J., Reiman, H. M., Cha, S. S., Wieand, H. S., Katzmann, J. A., Paulsen, J. K., and Moertel, C. G. (1991). DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68, 879-888.
118. Zambetti, M., Bonadonna, G., Valagussa, P., Daidone, M. G., Coradini, D., Bignami, P., Contesso, G., and Silvestrini, R. (1992). Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer. NCI Monogr. 11, 77-83.